Skip to main content
$9.68 $0.35 (3.8%)

03:44 PM EDT on 08/04/21

Amicus Therapeutics, Inc. (NASDAQ:FOLD)

CAPS Rating: 3 out of 5

A clinical-stage biopharmaceutical company, which focused on the discovery, development and commercialization of novel small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases.

Current Price $9.68 Mkt Cap $2.5B
Open $9.26 P/E Ratio 0.00
Prev. Close $0.00 Div. (Yield) $0.00 (0.0%)
Daily Range $9.24 - $9.80 Volume 3,004,644
52-Wk Range $8.60 - $25.39 Avg. Daily Vol. 2,313,556

Caps

How do you think NASDAQ:FOLD will perform against the market?

Add Stock to CAPS Watchlist

All Players

92 Outperform
19 Underperform
 

All-Star Players

15 Outperform
5 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:FOLD Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

colbydrf (< 20)
Submitted September 25, 2014

It has been doing well, and it may represent a market niche. It is worth tracking, at least.

zzlangerhans (98.48)
Submitted December 03, 2012

Amicus is showing another upward kick in advance of data from Study 011 of Amigal in Fabry's disease, with topline results likely to be released this month. Similar upward movements earlier this year have not been sustained. I've been dubious about… More

Recent Community Commentary

Read the most recent pitches from players about FOLD.

Recs

0
Member Avatar DaytradingStars (49.08) Submitted: 5/30/2020 2:56:10 AM : Outperform Start Price: $12.34 NASDAQ:FOLD Score: -66.15

SS10

Recs

0
Member Avatar LohShiSan (94.00) Submitted: 5/9/2020 3:01:51 AM : Outperform Start Price: $9.85 NASDAQ:FOLD Score: -18.06

Amicus Therapeutics specializes in developing better therapies to help patients suffering from ultra-orphan diseases, including lysosomal storage disorders (LSDs). As one of its lead programs has already been well received post-launch, one analyst believes the healthcare company’s future is only getting brighter.Its oral pharmaco-chaperone drug, Galafold, for Fabry, generated hefty sales of $55.3 million in Q4 2019. Not only did this top-line number beat the Street’s $49.7 million call, but it also surpassed Cowen analyst Ritu Baral’s $50.5 million estimate.Not to mention this result represents 13% quarter-over-quarter growth. Even though FOLD had a net loss of $91 million during the quarter and SG&A expense gained 9% quarter-over-quarter, it should be noted that this was in part caused by the expanded geographic scope of the launch of Galafold into Japan and the U.S.Baral added, “FOLD projects YE20 Galafold sales of $250-$260 million that would represent 37-43% year-over-year growth. Projected growth assumes maturing uptake in the EU top 5 countries (market share changing from ERT-switch to ERT-naive) and continued rapid uptake in US and non-top 5 EU countries. FOLD expects to see commercial sales from Latin American countries in 2021 to further drive topline growth.” To top it all off, GTx pipeline development is continuing. CLN6 follow-up and initial CLN3 data are both slated for the second half of 2020.It should come as no surprise, then, that Baral kept an “outperform” call and $31 price target on the stock. This conveys her confidence in FOLD’s ability to soar 174% in the next year. As for the rest of the Street, other analysts are in agreement. With three “buys” and one “hold,” the word on the Street is that the healthcare name is a “strong buy.” Based on the $21.17 average price target, shares could climb 87% higher in the next twelve months.

Recs

0
Member Avatar Speedylove (33.88) Submitted: 1/27/2016 4:46:27 PM : Outperform Start Price: $5.93 NASDAQ:FOLD Score: -68.01

New treatment for Fabreze

Leaderboard

Find the members with the highest scoring picks in FOLD.

Score Leader

dcsilver

dcsilver (< 20) Score: +599.88

The Score Leader is the player with the highest score across all their picks in FOLD.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
qubit15 21.34 1/21/2009 Underperform NS $7.91 +22.63% +449.28% +426.65 0 Comment
anticitradeshort 28.57 4/20/2009 Underperform NS $8.75 +10.86% +419.29% +408.43 0 Comment
OOji 26.91 1/12/2009 Underperform 1Y $7.60 +27.63% +403.59% +375.96 0 Comment
epc53 26.27 5/27/2009 Underperform 5Y $6.90 +40.58% +385.81% +345.23 0 Comment
BetapegAnalytics < 20 8/13/2009 Underperform 5Y $9.91 -2.10% +337.33% +339.43 0 Comment
portefeuille2 98.90 4/16/2014 10/31/2019 Outperform 5Y $1.83 +431.51% +136.62% +294.88 0 Comment
portefeuille12 25.25 4/25/2014 Outperform 5Y $1.84 +427.17% +135.53% +291.64 0 Comment
ArmstrongMan 91.82 7/24/2008 6/2/2011 Underperform 3Y $14.92 -34.99% +253.44% +288.43 0 Comment
bmoreNJ 65.56 8/28/2008 Underperform 3M $13.80 -29.71% +249.11% +278.82 0 Comment
portefeuille 98.51 4/4/2014 5/31/2021 Outperform NS $2.06 +370.87% +134.94% +235.93 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for FOLD.